AXS-14 (esreboxetine)

DRUG2 trials

Sponsors

Axsome Therapeutics, Inc.

Conditions

Fibromyalgia

Phase 3

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

RecruitingNCT07398417

Axsome Therapeutics, Inc.Fibromyalgia

Start: 2026-01-14End: 2028-03-01Target: 620Updated: 2026-09-04

Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

Enrolling by invitationNCT07637162

Axsome Therapeutics, Inc.Fibromyalgia

Start: 2026-04-29End: 2028-05-01Target: 300Updated: 2026-09-04